Penumbra Imaging Collaborative Study (PICS)
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
First received: November 3, 2008
Last updated: February 4, 2014
Last verified: February 2014
The primary aim of this study are to gather data on the "real world" experience of the Penumbra System and to determine if there is a correlate between the imaging-defined size of the ischemic penumbra at admission and patient outcome in patients already treated by the System. This will be accomplished by the collection of all available admission imaging data along with patient clinical and functional outcome results at 90-day follow-up to determine if a positive association exists between these variables. A secondary aim is to collect and summarize the 90-day functional outcome data for the purpose of sample size estimation for a potential randomized concurrent controlled trial. This will be accomplished by collecting the data on 90-day modified Rankin Scores (mRS) and all cause mortality.
Device: Penumbra System
||Observational Model: Cohort
Time Perspective: Prospective
||Penumbra Imaging Collaborative Study (PICS): A Multicenter Trial to Assess Outcome of Patients Revascularized by the Penumbra™ System
Primary Outcome Measures:
- Proportion of patients with an imaging-defined ischemic penumbra at admission that warrants revascularization by the Penumbra System. [ Time Frame: Admission ] [ Designated as safety issue: No ]
- Proportion of patients with successful revascularization of the occluded target vessel as defined by a TIMI score of 2 or 3 following use of the Penumbra System. [ Time Frame: Post-Procedure ] [ Designated as safety issue: No ]
- The proportion of patients with a modified Rankin Score (mRS) of ≤2 at 90 days post-procedure. [ Time Frame: 90-Days Post-Procedure ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Neurological status as defined by the National Institute of Health Stroke Scale (NIHSS) scores at Admission and Discharge. [ Time Frame: Admission and Discharge ] [ Designated as safety issue: No ]
- Incidence of intracranial hemorrhage. [ Time Frame: 24-Hours Post-Procedure ] [ Designated as safety issue: No ]
- Incidence of device-related serious adverse events. [ Time Frame: During the Procedure ] [ Designated as safety issue: No ]
- All cause mortality at 90 days post-procedure. [ Time Frame: 90-Days Post-Procedure ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||June 2014 (Final data collection date for primary outcome measure)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
A stroke cohort who were revacularized by the Penumbra System
- All patients who signed informed consent and revascularized by the Penumbra™ System in accordance to the Instruction For Use are eligible for this study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00785161
|Swedish Medical Center
|Englewood, Colorado, United States, 80113 |
||Siu Po Sit, PhD
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 3, 2008
||February 4, 2014
||United States: Institutional Review Board
Keywords provided by Penumbra Inc.:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 24, 2014
Central Nervous System Diseases
Nervous System Diseases